Abstract
The considerable pharmacologic differences among atypical antipsychotic agents and the specific clinical circumstances of individual patients with psychiatric illness require the availability of a full range of agents in this class. Restrictions in the availability of atypical agents may prove to be counterproductive, both clinically and economically. Elderly individuals and those from minority groups may be particularly disadvantaged by restrictions placed on these agents. Additional clinical studies in large populations with different forms of schizophrenia and varied clinical histories are required to determine the appropriateness of specific atypical agents in patient subgroups. Advances in knowledge of the molecular genetics of schizophrenia and the receptor properties of individual drugs will help the clinician determine which drug and dosage are best for each individual patient. This will eventually replace the “hit or miss” process that characterizes current practice. Because of variations in response to atypical agents, the clinical vulnerability of patients with psychiatric illness, the difficulties they have in adapting to changes and adhering to medication regimens, and our poor understanding of the molecular basis of schizophrenia and its treatment, prescription insurance plans should provide access to a broad range of atypical agents.
Similar content being viewed by others
References
Wakade CG, Mahadik SP, Waller JL, Chiu FC. Atypical neuroleptics stimulate neurogenesis and the adult rat brain.J Neurosci Res. 2002;69:72–79.
Lieberman JA, Tollefson GD, Charles C, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis.Arch Gen Psychiatry. 2005;62:361–370.
American Association for Geriatric Psychiatry (AAGP).Position Paper on Formulary Choices and Restrictions. Bethesda, Md: AAGP; 1997.
MedPAC. Dual eligible beneficiaries. Available at: http://www.medpac.gov/publications/ congressional_reports/Jun04DatabookSec2.pdf. June 30, 2007.
Donohue J. Mental health in the Medicare Part D benefit: a new regulatory model?Health Affairs. 2006;25:707–719.
Morden NE, Garrison LP Jr. Implications of Part D for mentally ill dual eligibles: a challenge for Medicare.Health Affairs. 2006;25:491–500.
Smedley BD, Stith AY, Nelson AR, eds.Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: The National Academies Press; 2003.
Opolka JL, Rascati KL, Brown CM, Gibson PJ. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine.Psychiatr Serv. 2004;55:151–156.
Henderson D. Ethnopharmacology update. Presented at: The American Psychiatric Association 2005 Annual Meeting; May 21–26, 2005; Atlanta, Ga. Symposium No. 15A.
Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better.J Clin Psychiatry. 2003;64:1308–1315.
Surles RC. Atypical antipsychotics: considerations for Medicaid coverage.Am J Manag Care. 2005;11(suppl):S248-S253.
Kane JM. Schizophrenia.N Engl J Med. 1996;334:34–41.
Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia.Psychiatr Serv. 2004;55:886–891.
Muller N. Mechanisms of relapse prevention in schizophrenia.Pharmacopsychiatry. 2004; 37(suppl 2):S141-S147.
Tandon R, Nasrallah HA. The diagnosis and treatment of schizophrenia in primary care: Medscape Psychiatry and Mental Health CME Program. Available at: http://www.medscape.com/ viewprogram/5902. Accessed September 13, 2006.
Parikh V, Evans DR, Khan MM, Mahadik SP. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome.Schizophrenia Res. 2003;60:117–123.
Osterberg L, Blaschke T. Adherence to medication.N Engl J Med. 2005;353:487–497.
Chue PS, Heeg BMS, Buskens E, van Hout BA. Modeling the impact of compliance on the costs and effects of long-acting risperidone in Canada.PharmacoEconomics. 2005;23(suppl 1):62–74.
Edwards NC, Rupnow MF, Pashos CL, Botteman MF, Diamond RJ. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.PharmacoEconomics. 2005;23(suppl 1):299–314.
Soumerai S. Unintended outcomes of Medicaid drug cost-containment policies on the chronically mentally ill.J Clin Psychiatry. 2003;64(suppl 17):19–22.
Tamblyn R. Evaluation report on the impact of the prescription drug insurance plan: Summary Report submitted to the Ministere de la Sante et des Services Sociaux du Quebec, March 1999.
Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost sharing among poor and elderly persons.JAMA. 2001;285:421–429.
Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid: AARP research report #2004–04, March 2004, Washington, DC. Available at: http://assets.aarp.org/ rgcenter/health/2004_04_access.pdf. Accessed November 6, 2006.
Committee for Program Review and Investigations, Legislative Research Commission. Program evaluation of the Kentucky Medicaid Drug File and Prior Authorization System: report on the impact of prior authorization for Zyprexa. Research Report No. 281, November 2003. Frankfort, Kentucky: Kentucky Medicaid Program; May 1999.
Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum A, Aquila R. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.Value Health. 2006;9:77–89.
Soumerai S. Implications of research on drug cost containment for the Medicare drug benefit: balancing access, affordability and innovation. Presented at: The Health Industry Forum, Balancing Access, Affordability, and Innovation: Pharmaceutical Benefit Management Under Medicare Part D; July 13, 2006; Waltham, Mass.
McCombs J.Anti-psychotics and interchangeability. Presented at: The P& T Society 6th Annual Conference: Impact of Public Policy vs. Market Reality; October 26–27, 2006; Washington, DC.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.N Engl J Med. 2005;353:1209–1223.
Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.Am J Psychiatry. 2003;160:1209–1222.
Rosack J. Government antipsychotic study finds no clear winner in “horse race.”Psychiatric News. October 21, 2005;40:1.
National Alliance on Mental Illness. CATIE raises more questions than it answers. Available at: http://www.nami.org/Template.cfm?Section=CATIE&Template=/ContentManagement/ ContentDisplay.cfm&ContentID=27164. Accessed November 3, 2006.
Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.Am J Psychiatry. 2007;164:415–427.
NIMH perspective on antipsychotic reimbursement: using results from CATIE, October 31, 2005. Available at: http://www.nami.org/Template.cfm?Section=CATIE&Template=/ ContentManagement/ContentDisplay.cfm&ContentID=27931. Accessed October 19, 2006.
Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Effectiveness of switching antipsychotic medications.Am J Psychiatry. 2006;163:2090–2095.
Tamminga C. Practical treatment information for schizophrenia.Am J Psychiatry. 2006;163:563–565.
Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor activity predicts short-term weight gain for typical and atypical antipsychotic drugs.Neuropsychopharmacology. 2003;28:519–526.
American Psychiatric Association (APA).Practice Guideline for the Treatment of Patients With Schizophrenia. 2nd ed. Arlington, Va: APA; 2004.
Keefe RS. Comparison of atypicals in first-episode psychosis: a randomized, 52-week comparison of olanzapine, quetiapine, and risperidone. Presented at: 18th Congress of the European College of Neuropsychopharmacology; October 22–25, 2005; The Netherlands. Late-Breaking Session, Abstract 5.
Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.Schizophrenia Bull. 1999;25:201–222.
Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.Schizophrenia Bull. 1999;25:233–355.
Meltzer HY, Lee MA, Ranjan R. Recent advances in the pharmacotherapy of schizophrenia.Acta Psychiatr Scand. 1994;90(suppl):95–101.
Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response.Lancet. 2000;55:1615–1616.
Mizutani T. Frequencies of major CYPs in Asians and Caucasians.Drug Metab Rev. 2003;35:99–106.
De Leon J, Susce MT, Pan R-M, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.Clin Psychiatry. 2005;66:15–27.
Chou WH, Yan FX, de Leon J, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.J Clin Psychopharmacol. 2000;20:246–251.
Ginsberg DL, ed. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry.CNS Spectr. 2006;11 (suppl 3):1–16.
de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharma-cogenetic testing for CYP450 2D6 and CYP450 2C19.Psychosomatics. 2006;47:75–85.
Sharif ZA. Pharmacokinetics, metabolism, and drug-drug interactions of atypical antipsychotics in specialized populations.J Clin Psychiatry. 2003;5(suppl 6):22–25.
Scharfetter J. Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia—an update.Pharmacogenomics. 2004;5:691–698.
Lencz T, Robinson DG, Xu K, et al. DRT2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.Am J Psychiatry. 2006;163:529–531.
Lane HY, Lee CC, Liu YC, Chang WH. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.Pharmacogenomics. 2005;6:139–149.
Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response.Am J Psychiatry. 2004;161:780–796.
Ruaño G, Goethe JW, Caley C, et al. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.Mol Psychiatry. 2007;12:474–482.
Wilffert B, Zaal R, Brouwers JR. Pharmacogenetics as a tool in the therapy of schizophrenia.Pharm World Sci. 2005;27:20–30.
Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis.Pharmacogenet Genomics. 2005;15:195–200.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, E., Levy, R. & Pikalov, A. Personalized treatment with atypical antipsychotic medications. Adv Therapy 24, 721–740 (2007). https://doi.org/10.1007/BF02849966
Issue Date:
DOI: https://doi.org/10.1007/BF02849966